IL272245B2 - שיטות לטיפול בדלקת ושט אאוזינופילית פעילה - Google Patents

שיטות לטיפול בדלקת ושט אאוזינופילית פעילה

Info

Publication number
IL272245B2
IL272245B2 IL272245A IL27224520A IL272245B2 IL 272245 B2 IL272245 B2 IL 272245B2 IL 272245 A IL272245 A IL 272245A IL 27224520 A IL27224520 A IL 27224520A IL 272245 B2 IL272245 B2 IL 272245B2
Authority
IL
Israel
Prior art keywords
patient
eoe
pathway inhibitor
inhibitor
dose
Prior art date
Application number
IL272245A
Other languages
English (en)
Other versions
IL272245B1 (he
IL272245A (he
Inventor
Allen Radin
Jennifer D Hamilton
Leda Mannent
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Allen Radin
Jennifer D Hamilton
Leda Mannent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Sanofi Biotechnology, Allen Radin, Jennifer D Hamilton, Leda Mannent filed Critical Regeneron Pharma
Priority claimed from PCT/US2018/045195 external-priority patent/WO2019028367A1/en
Publication of IL272245A publication Critical patent/IL272245A/he
Publication of IL272245B1 publication Critical patent/IL272245B1/he
Publication of IL272245B2 publication Critical patent/IL272245B2/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL272245A 2017-08-04 2018-08-03 שיטות לטיפול בדלקת ושט אאוזינופילית פעילה IL272245B2 (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US201762561593P 2017-09-21 2017-09-21
EP18305252 2018-03-08
PCT/US2018/045195 WO2019028367A1 (en) 2017-08-04 2018-08-03 METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES

Publications (3)

Publication Number Publication Date
IL272245A IL272245A (he) 2020-03-31
IL272245B1 IL272245B1 (he) 2024-10-01
IL272245B2 true IL272245B2 (he) 2025-02-01

Family

ID=63113646

Family Applications (2)

Application Number Title Priority Date Filing Date
IL315556A IL315556A (he) 2017-08-04 2018-08-02 שיטות לטיפול בדלקת ושט אאוזינופילית פעילה
IL272245A IL272245B2 (he) 2017-08-04 2018-08-03 שיטות לטיפול בדלקת ושט אאוזינופילית פעילה

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL315556A IL315556A (he) 2017-08-04 2018-08-02 שיטות לטיפול בדלקת ושט אאוזינופילית פעילה

Country Status (9)

Country Link
EP (1) EP3661551A1 (he)
JP (2) JP7417515B2 (he)
KR (2) KR20240152980A (he)
CN (1) CN111032084A (he)
AU (2) AU2018311981B2 (he)
CA (1) CA3071528A1 (he)
IL (2) IL315556A (he)
MA (1) MA49744A (he)
MX (2) MX2020001305A (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115768516A (zh) * 2020-05-22 2023-03-07 瑞泽恩制药公司 通过施用il-4r抑制剂治疗嗜酸细胞性食管炎的方法
JP2025516245A (ja) * 2022-04-29 2025-05-27 中山康方生物医▲藥▼有限公司 抗ヒトｉｌ－４ｒａの抗体及びその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006571A1 (en) * 2013-07-11 2015-01-15 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015061441A1 (en) * 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
UY36578A (es) * 2015-03-11 2016-09-30 Glaxosmithkline Ip Dev Ltd Proteínas de unión a tslp

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006571A1 (en) * 2013-07-11 2015-01-15 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
E S DELLON ET AL,, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL RECOMBINANT, HUMANIZED, ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY (RPC4046) IN PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS: RESULTS OF THE HEROES STUDY, 14 October 2016 (2016-10-14) *
MARC E. ROTHENBERG ET AL,, INTRAVENOUS ANTI-IL-13 MAB QAX576 FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS, 1 February 2015 (2015-02-01) *

Also Published As

Publication number Publication date
CN111032084A (zh) 2020-04-17
JP2020529434A (ja) 2020-10-08
MX2024012777A (es) 2024-11-08
JP7417515B2 (ja) 2024-01-18
IL272245B1 (he) 2024-10-01
KR102719720B1 (ko) 2024-10-22
AU2018311981B2 (en) 2024-11-14
MX2020001305A (es) 2020-03-09
JP2024016237A (ja) 2024-02-06
RU2020109331A3 (he) 2021-12-28
CA3071528A1 (en) 2019-02-07
KR20240152980A (ko) 2024-10-22
EP3661551A1 (en) 2020-06-10
AU2025200955A1 (en) 2025-03-06
AU2018311981A1 (en) 2020-02-20
IL272245A (he) 2020-03-31
RU2020109331A (ru) 2021-09-06
MA49744A (fr) 2020-06-10
IL315556A (he) 2024-11-01
KR20200035442A (ko) 2020-04-03

Similar Documents

Publication Publication Date Title
US11053309B2 (en) Methods for treating active eosinophilic esophagitis
US12291571B2 (en) Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody
AU2025200955A1 (en) Methods for treating active eosinophilic esophagitis
RU2776651C2 (ru) Способы лечения активного эозинофильного эзофагита
HK40029391A (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
HK1218854B (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor